Cantuzumab ravtansine
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | MUC1 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4).[1] It uses a more hindered disulfide linkage than cantuzumab mertansine.[2]
See also
- Cantuzumab mertansine
- ImmunoGen Inc, developer of DM4 based drugs
References
- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2). Archived from the original (PDF) on April 1, 2012.
- ^ Goldmacher VS, Singh R, Chittenden T, Kovtun Y (2013). "Linker technology and impact of linker design on ADC properties.". In Phillips GL (ed.). Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications. New York: Springer. pp. 117–135 (131). ISBN 978-1-4614-5456-4.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles with changed KEGG identifier
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Immunology
- Monoclonal antibodies
- Antibody-drug conjugates
- All stub articles
- Monoclonal antibody stubs